{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:24:48Z","timestamp":1760783088573},"reference-count":27,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2008,12,12]],"date-time":"2008-12-12T00:00:00Z","timestamp":1229040000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Dialysis"],"published-print":{"date-parts":[[2009,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>There has been a dramatic sea change in the use of erythropoiesis\u2010stimulating agents (ESAs) for anemic persons with chronic kidney disease (CKD) or cancer patients undergoing chemotherapy. An important area that has not been addressed previously is a CKD patient who also has a malignancy. Clinical guidelines exist that outline recommended treatments for each disease, but the intersection of the two disease processes presents difficult decisions for patients and physicians. Herein, we review the background underlying recent revisions in clinical alerts and guidelines for ESAs, and provide guidance for treating anemia among CKD patients who are receiving no therapy, chemotherapy with curative intent, or chemotherapy with palliative intent. The guiding principle is that comprehensive assessment of risks and benefits in the relevant clinical setting is imperative.<\/jats:p>","DOI":"10.1111\/j.1525-139x.2008.00524.x","type":"journal-article","created":{"date-parts":[[2008,12,12]],"date-time":"2008-12-12T09:21:32Z","timestamp":1229073692000},"page":"1-4","source":"Crossref","is-referenced-by-count":16,"title":["<i>Editorial<\/i>: Intersecting Guidelines: Administering Erythropoiesis\u2010Stimulating Agents to Chronic Kidney Disease Patients with Cancer"],"prefix":"10.1111","volume":"22","author":[{"given":"Charles L.","family":"Bennett","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela S.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric H.","family":"Kraut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athena T.","family":"Samaras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis P.","family":"West","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,2,20]]},"reference":[{"key":"e_1_2_6_2_2","volume-title":"Cancer Prevalence in Patients with End\u2010Stage Renal Disease","author":"Xue JL","year":"2007"},{"key":"e_1_2_6_3_2","volume-title":"Drugs at FDA","author":"U.S. Food and Drug Administration"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(96)00306-5"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2007.12.013"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.FP0050966"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2005.04.016"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062276"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065485"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808273390903"},{"key":"e_1_2_6_11_2","volume-title":"Food and Drug Administration Center for Drug Evaluation and Research Joint Meeting of the Cardiovascular and Renal Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee September","year":"2007"},{"key":"e_1_2_6_12_2","first-page":"3561","article-title":"Erythropoietin and erythropoietin receptor expression in human cancer","volume":"61","author":"Acs G","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14567-9"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.150"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.2737"},{"key":"e_1_2_6_16_2","volume-title":"Medscape Medical News, June 10, 2008","author":"New Study Probes Safety of Erythropoiesis\u2010Stimulating Agents"},{"key":"e_1_2_6_17_2","article-title":"Predictive testing for erythropoietin induced tumor progression in head and neck cancer","volume":"26","author":"Blau CA","year":"2008","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.299.8.914"},{"key":"e_1_2_6_19_2","volume-title":"American Association for Cancer Research Annual Meeting Proceedings","author":"Glaspy J","year":"2007"},{"key":"e_1_2_6_20_2","volume-title":"Continuing Reassessment of the Risks of Erythropoiesis\u2010Stimulating Agents (ESAs) Administered for the Treatment of Anemia Associated with Cancer Chemotherapy","author":"Oncologic Drugs Advisory Committee","year":"2007"},{"key":"e_1_2_6_21_2","volume-title":"FDA Briefing Document","author":"Oncologic Drugs Advisory Committee","year":"2008"},{"key":"e_1_2_6_22_2","volume-title":"NCCN Clinical Practice Guidelines in Oncology: Cancer and Chemotherapy\u2010Induced Anemia","author":"National Comprehensive Cancer Network"},{"key":"e_1_2_6_23_2","volume-title":"EMEA Recommends a New Warning for Epoetins for their Use in Cancer Patients","author":"Press Release","year":"2008"},{"key":"e_1_2_6_24_2","volume-title":"FDA Complete Response and Labeling Change Order, Epogen","year":"2008"},{"key":"e_1_2_6_25_2","volume-title":"FDA Complete Response and Labeling Change Order, Aranesp","year":"2008"},{"key":"e_1_2_6_26_2","volume-title":"Erythropoiesis Stimulating Agents (ESAs) in Cancer and Related Neoplastic Conditions","author":"Centers for Medicare and Medicaid Studies","year":"2007"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.6.1657"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2405062"}],"container-title":["Seminars in Dialysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1525-139X.2008.00524.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1525-139X.2008.00524.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T19:37:53Z","timestamp":1697312273000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1525-139X.2008.00524.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["10.1111\/j.1525-139X.2008.00524.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1525-139x.2008.00524.x","archive":["Portico"],"relation":{},"ISSN":["0894-0959","1525-139X"],"issn-type":[{"value":"0894-0959","type":"print"},{"value":"1525-139X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}